Related Experiment Videos
Aggressive non-Hodgkin's lymphoma: T-cell versus B-cell
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
Hematological Oncology
|March 1, 1996
Summary
This study on non-Hodgkin's lymphoma found that while T-cell lymphomas present differently, immunophenotype isn't a key independent prognostic factor. Advanced stage and B symptoms significantly impact patient outcomes.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Non-Hodgkin's lymphoma (NHL) encompasses diverse subtypes with varying clinical behaviors.
- Understanding prognostic factors is crucial for tailoring treatment strategies in NHL.
Purpose of the Study:
- To define clinical characteristics, treatment outcomes, and prognostic factors in T-cell and B-cell non-Hodgkin's lymphomas.
- To determine the independent prognostic significance of immunophenotype in NHL.
Main Methods:
- Retrospective analysis of 144 T-cell and 357 B-cell non-Hodgkin's lymphoma patients.
- Exclusion of entities with well-defined immunophenotype and clinical characteristics.
- Univariate and multivariate analyses to identify prognostic factors.
Main Results:
- T-cell lymphomas were associated with younger patients, advanced disease, and B symptoms, but less bulky disease.
- Primary nasal lymphomas were typically T-cell, while gastrointestinal and Waldeyer's ring lymphomas were predominantly B-cell.
- Multivariate analysis identified advanced stage, B symptoms, age, high LDH, and non-doxorubicin regimens as poor prognostic factors; immunophenotype was not significant.
Conclusions:
- Immunophenotype is not an independent prognostic factor in this cohort of non-Hodgkin's lymphoma.
- Disease stage, systemic symptoms, patient age, and specific treatment regimens are critical prognostic indicators.